Laparoscopy-assisted versus open surgery for low rectal cancer (LASRE): 3-year survival outcomes of a multicentre, randomised, controlled, non-inferiority trial

IF 30.9 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY
Weizhong Jiang, Jianmin Xu, Ming Cui, Huizhong Qiu, Ziqiang Wang, Liang Kang, Haijun Deng, Weiping Chen, Qingtong Zhang, Xiaohui Du, Chunkang Yang, Yincong Guo, Ming Zhong, Kai Ye, Jun You, Dongbo Xu, Xinxiang Li, Zhiguo Xiong, Kaixiong Tao, Kefeng Ding, Zhizhong Pan
{"title":"Laparoscopy-assisted versus open surgery for low rectal cancer (LASRE): 3-year survival outcomes of a multicentre, randomised, controlled, non-inferiority trial","authors":"Weizhong Jiang, Jianmin Xu, Ming Cui, Huizhong Qiu, Ziqiang Wang, Liang Kang, Haijun Deng, Weiping Chen, Qingtong Zhang, Xiaohui Du, Chunkang Yang, Yincong Guo, Ming Zhong, Kai Ye, Jun You, Dongbo Xu, Xinxiang Li, Zhiguo Xiong, Kaixiong Tao, Kefeng Ding, Zhizhong Pan","doi":"10.1016/s2468-1253(24)00273-5","DOIUrl":null,"url":null,"abstract":"<h3>Background</h3>Laparoscopic surgery is increasingly used for rectal cancer, but the long-term oncological outcomes for low rectal cancer have not been fully established. We aimed to evaluate the 3-year survival outcomes of laparoscopic surgery versus open surgery in the treatment of low rectal cancer.<h3>Methods</h3>This multicentre, randomised, controlled, non-inferiority trial was conducted at 22 tertiary hospitals in China. Individuals aged 18–75 years with histologically confirmed cT1–2N0, cT3–4aN0, or cT1–4aN1–2 rectal adenocarcinoma within 5 cm from the dentate line were eligible for inclusion. Participants were randomly assigned (2:1) to undergo laparoscopic surgery or open surgery. Central randomisation was conducted using a web response system, and was stratified by clinical stage, age, sex, BMI, and American Society of Anesthesiologists classification. Investigators, patients and statisticians were not masked to group allocation. The primary outcome was 3-year disease-free survival, defined as the time from the date of surgery to the date of locoregional recurrence, distant metastasis, or death from any cause, whichever occurred first. Non-inferiority was defined as a lower limit of one-sided 97·5% CI for group difference (laparoscopic surgery group minus open surgery group) of greater than –10%. The primary analyses were performed in the modified intention-to-treat population, which excluded patients with distant metastasis discovered during surgery and those who did not undergo surgery or underwent local resection only. The trial is registered with <span><span>ClinicalTrials.gov</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>, <span><span>NCT01899547</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>, and has been completed.<h3>Findings</h3>Between Nov 12, 2013, and June 6, 2018, 1070 patients were enrolled and randomly assigned to treatment. 1039 patients (685 in the laparoscopic surgery group and 354 in the open surgery group; median age 57 years, IQR 50 to 64; 620 [60%] male and 419 [40%] women) were included in the modified intention-to-treat analysis. 3-year disease-free survival was 81·4% (95% CI 78·2 to 84·1) in the laparoscopic surgery group and 79·8% (75·2 to 83·6) in the open surgery group (hazard ratio [HR] 0·92, 95% CI 0·69 to 1·23; p=0·56). The difference between groups was 1·60% (one-sided 97·5% CI –3·34 to ∞, p&lt;0·0001 for non-inferiority). 3-year overall survival was 91·7% (95% CI 89·3 to 93·5) in the laparoscopic surgery group and 93·7% (90·6 to 95·8) in the open surgery group (HR 1·34, 95% CI 0·82 to 2·19; p=0·24). 3-year locoregional recurrence was 3·7% (95% CI 2·5 to 5·3) and 2·3% (1·1 to 4·3), respectively (HR 1·64, 95% CI 0·74 to 3·63; p=0·22). 5-year overall survival was 84·6% (95% CI 81·5 to 87·1) and 86·6% (82·5 to 89·8) in the open group (HR 1·16, 95% CI 0·82 to 1·64; p=0·41).<h3>Interpretation</h3>Laparoscopic surgery performed by experienced surgeons is non-inferior to open surgery for 3-year disease-free survival among patients with low rectal cancer. These results support the use of laparoscopic surgery for low rectal cancer.<h3>Funding</h3>The Key Clinical Specialty Discipline Construction Program of the National Health and Family Planning Commission of China; Minimally Invasive Medical Center Construction Program, Fujian Province, China; and Joint Funds for the Innovation of Science and Technology, Fujian Province, China.","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"244 1","pages":""},"PeriodicalIF":30.9000,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Gastroenterology & Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/s2468-1253(24)00273-5","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Laparoscopic surgery is increasingly used for rectal cancer, but the long-term oncological outcomes for low rectal cancer have not been fully established. We aimed to evaluate the 3-year survival outcomes of laparoscopic surgery versus open surgery in the treatment of low rectal cancer.

Methods

This multicentre, randomised, controlled, non-inferiority trial was conducted at 22 tertiary hospitals in China. Individuals aged 18–75 years with histologically confirmed cT1–2N0, cT3–4aN0, or cT1–4aN1–2 rectal adenocarcinoma within 5 cm from the dentate line were eligible for inclusion. Participants were randomly assigned (2:1) to undergo laparoscopic surgery or open surgery. Central randomisation was conducted using a web response system, and was stratified by clinical stage, age, sex, BMI, and American Society of Anesthesiologists classification. Investigators, patients and statisticians were not masked to group allocation. The primary outcome was 3-year disease-free survival, defined as the time from the date of surgery to the date of locoregional recurrence, distant metastasis, or death from any cause, whichever occurred first. Non-inferiority was defined as a lower limit of one-sided 97·5% CI for group difference (laparoscopic surgery group minus open surgery group) of greater than –10%. The primary analyses were performed in the modified intention-to-treat population, which excluded patients with distant metastasis discovered during surgery and those who did not undergo surgery or underwent local resection only. The trial is registered with ClinicalTrials.gov, NCT01899547, and has been completed.

Findings

Between Nov 12, 2013, and June 6, 2018, 1070 patients were enrolled and randomly assigned to treatment. 1039 patients (685 in the laparoscopic surgery group and 354 in the open surgery group; median age 57 years, IQR 50 to 64; 620 [60%] male and 419 [40%] women) were included in the modified intention-to-treat analysis. 3-year disease-free survival was 81·4% (95% CI 78·2 to 84·1) in the laparoscopic surgery group and 79·8% (75·2 to 83·6) in the open surgery group (hazard ratio [HR] 0·92, 95% CI 0·69 to 1·23; p=0·56). The difference between groups was 1·60% (one-sided 97·5% CI –3·34 to ∞, p<0·0001 for non-inferiority). 3-year overall survival was 91·7% (95% CI 89·3 to 93·5) in the laparoscopic surgery group and 93·7% (90·6 to 95·8) in the open surgery group (HR 1·34, 95% CI 0·82 to 2·19; p=0·24). 3-year locoregional recurrence was 3·7% (95% CI 2·5 to 5·3) and 2·3% (1·1 to 4·3), respectively (HR 1·64, 95% CI 0·74 to 3·63; p=0·22). 5-year overall survival was 84·6% (95% CI 81·5 to 87·1) and 86·6% (82·5 to 89·8) in the open group (HR 1·16, 95% CI 0·82 to 1·64; p=0·41).

Interpretation

Laparoscopic surgery performed by experienced surgeons is non-inferior to open surgery for 3-year disease-free survival among patients with low rectal cancer. These results support the use of laparoscopic surgery for low rectal cancer.

Funding

The Key Clinical Specialty Discipline Construction Program of the National Health and Family Planning Commission of China; Minimally Invasive Medical Center Construction Program, Fujian Province, China; and Joint Funds for the Innovation of Science and Technology, Fujian Province, China.
腹腔镜辅助与开放手术治疗低位直肠癌(LASRE):多中心、随机对照、非劣效试验的 3 年生存结果
背景腹腔镜手术越来越多地用于直肠癌的治疗,但低位直肠癌的长期肿瘤治疗效果尚未完全确定。我们旨在评估腹腔镜手术与开腹手术治疗低位直肠癌的 3 年生存率。年龄在18-75岁之间、组织学确诊为距齿状线5厘米以内的cT1-2N0、cT3-4aN0或cT1-4aN1-2直肠腺癌的患者均可纳入试验。参与者被随机分配(2:1)接受腹腔镜手术或开腹手术。中央随机分配采用网络响应系统进行,并根据临床分期、年龄、性别、体重指数和美国麻醉学会分类进行分层。研究人员、患者和统计人员均不对组别分配蒙面。主要研究结果为3年无病生存期,即从手术之日起到局部复发、远处转移或因任何原因死亡(以先发生者为准)的时间。非劣效性定义为单侧97-5% CI的组间差异(腹腔镜手术组减去开放手术组)下限大于-10%。主要分析在修改后的意向治疗人群中进行,排除了手术中发现远处转移的患者以及未接受手术或仅接受局部切除的患者。该试验已在ClinicalTrials.gov注册,编号为NCT01899547,并已完成。研究结果2013年11月12日至2018年6月6日期间,1070名患者入组并被随机分配治疗。1039名患者(腹腔镜手术组685人,开放手术组354人;中位年龄57岁,IQR 50至64岁;男性620人[60%],女性419人[40%])被纳入修改后的意向治疗分析。腹腔镜手术组的3年无病生存率为81-4%(95% CI 78-2至84-1),开腹手术组为79-8%(75-2至83-6)(危险比[HR] 0-92,95% CI 0-69至1-23;P=0-56)。组间差异为1-60%(单侧97-5% CI -3-34至∞,非劣效性p<0-0001)。腹腔镜手术组的3年总生存率为91-7%(95% CI为89-3至93-5),开腹手术组为93-7%(90-6至95-8)(HR为1-34,95% CI为0-82至2-19;P=0-24)。3年局部复发率分别为3-7%(95% CI 2-5至5-3)和2-3%(1-1至4-3)(HR 1-64,95% CI 0-74至3-63;P=0-22)。开腹组的5年总生存率为84-6%(95% CI 81-5至87-1),开腹组为86-6%(82-5至89-8)(HR 1-16,95% CI 0-82至1-64;P=0-41)。这些结果支持使用腹腔镜手术治疗低位直肠癌。基金资助国家卫生和计划生育委员会临床重点专科建设项目、福建省微创医学中心建设项目、福建省科技创新联合基金。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
50.30
自引率
1.10%
发文量
0
期刊介绍: The Lancet Gastroenterology & Hepatology is an authoritative forum for key opinion leaders across medicine, government, and health systems to influence clinical practice, explore global policy, and inform constructive, positive change worldwide. The Lancet Gastroenterology & Hepatology publishes papers that reflect the rich variety of ongoing clinical research in these fields, especially in the areas of inflammatory bowel diseases, NAFLD and NASH, functional gastrointestinal disorders, digestive cancers, and viral hepatitis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信